Altimmune stock
ALTNASDAQAltimmune, Inc., HealthcareISIN US02155H2004
25Score 25 out of 100, Weak
Price and trend
37 / 100
Price history
−62% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 49% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 74% below its 52-week high. Largest decline in 9 years: 99% (May 2017 to November 2019).
Chart figures for advanced users
- SMA 50$2.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.15
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.61
- The lowest closing price of the last twelve months.
- Resistance$6.18
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Altimmune, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $313.17M, is number 271 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $41K (up 105% year on year) and a loss of $88.09M.
- MEQIRI Score 25 out of 100 (Weak): rank 712 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $326.32M, financial debt $35.75M.Stability 53
Weaknesses
- DilutionShare count up 244% since 2020.Capital allocation 18
- Revenue shrinkingRevenue down 65.3% a year since 2020.Growth 32
- Loss-makingLoss of $91.76M over the last 12 months.Fundamentals 17
The score is held back by profitability and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 105% on the prior year. Revenue swung sharply, with 1 of 20 years negative.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −230461%, net −214861%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 12 Nov 2026EPS reported −$0.15 (expected −$0.13)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.580.0%
- Revenue
- $1.88K0.0%
- Earnings per share
- −$0.640.0%
- Revenue
- $25.73M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.0%No change stated: top-line data from the RESTORE trial expected in the second half of 2027, cash runway covers the Phase III readout in 2029.
“In ALD, we are pleased to report that we completed patient enrollment in the RESTORE trial and expect top-line data in the second half of 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $44,250 in total.
- Durso Jerome BenedictPurchase
13 Aug 2026, President and CEO
- Shares
- 15,000
- Price
- $2.95
- Value
- $44,250
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Altimmune
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 25
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- NeurogeneNGNE $396.64M34
- AlectorALEC $391.55M71
- ProKidneyPROK $379.97M27
- C4 TherapeuticsCCCC $379.51M35
- Fennec PharmaceuticalsFENC $373.11M52
- Sagimet BiosciencesSGMT $371.76M46
- Editas MedicineEDIT $365.52M28
- PepGenPEPG $363.83M43
ETFs that hold Altimmune
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.